Key Points
- CFO Kevin Feeley sold 3,855 shares on Dec. 16 for $143.87 each (totaling $554,618.85), cutting his position by 30.63% to 8,731 shares; he also sold 1,266 shares on Dec. 9 and 388 shares on Oct. 29.
- GeneDx beat Q3 estimates with $0.49 EPS vs. $0.28 expected and $116.74M revenue, while trading at a $3.94B market cap and an unusually high P/E of 1,514.67; analysts have a consensus "Moderate Buy" and an average target of $134.78.
GeneDx Holdings Corp. (NASDAQ:WGS - Get Free Report) CFO Kevin Feeley sold 3,855 shares of the business's stock in a transaction dated Tuesday, December 16th. The shares were sold at an average price of $143.87, for a total transaction of $554,618.85. Following the completion of the transaction, the chief financial officer owned 8,731 shares in the company, valued at $1,256,128.97. The trade was a 30.63% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website.
Kevin Feeley also recently made the following trade(s):
- On Tuesday, December 9th, Kevin Feeley sold 1,266 shares of GeneDx stock. The stock was sold at an average price of $159.28, for a total transaction of $201,648.48.
- On Wednesday, October 29th, Kevin Feeley sold 388 shares of GeneDx stock. The stock was sold at an average price of $136.54, for a total value of $52,977.52.
GeneDx Trading Up 0.3%
WGS opened at $136.32 on Friday. GeneDx Holdings Corp. has a one year low of $55.17 and a one year high of $170.87. The company has a debt-to-equity ratio of 0.18, a current ratio of 2.71 and a quick ratio of 2.59. The business has a 50 day simple moving average of $140.74 and a two-hundred day simple moving average of $115.51. The firm has a market capitalization of $3.94 billion, a price-to-earnings ratio of 1,514.67 and a beta of 1.99.
GeneDx (NASDAQ:WGS - Get Free Report) last posted its earnings results on Tuesday, October 28th. The company reported $0.49 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.28 by $0.21. GeneDx had a return on equity of 20.22% and a net margin of 0.52%.The firm had revenue of $116.74 million for the quarter, compared to analysts' expectations of $104.33 million. Analysts predict that GeneDx Holdings Corp. will post 0.97 EPS for the current year.
Analysts Set New Price Targets
Several brokerages recently issued reports on WGS. Zacks Research cut shares of GeneDx from a "strong-buy" rating to a "hold" rating in a research report on Thursday, October 2nd. Weiss Ratings reiterated a "sell (d)" rating on shares of GeneDx in a report on Wednesday, October 8th. Wells Fargo & Company set a $155.00 target price on GeneDx and gave the company an "equal weight" rating in a research note on Monday. BTIG Research increased their price objective on GeneDx from $165.00 to $200.00 and gave the stock a "buy" rating in a report on Friday, December 12th. Finally, Wall Street Zen cut shares of GeneDx from a "buy" rating to a "hold" rating in a report on Saturday, November 1st. Seven investment analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average target price of $134.78.
View Our Latest Stock Analysis on GeneDx
Institutional Trading of GeneDx
Several institutional investors have recently bought and sold shares of WGS. Zurcher Kantonalbank Zurich Cantonalbank boosted its stake in shares of GeneDx by 5.1% in the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,702 shares of the company's stock worth $399,000 after buying an additional 181 shares during the last quarter. Jones Financial Companies Lllp boosted its position in GeneDx by 664.3% in the third quarter. Jones Financial Companies Lllp now owns 214 shares of the company's stock worth $25,000 after purchasing an additional 186 shares during the last quarter. Quarry LP increased its position in shares of GeneDx by 248.8% during the 3rd quarter. Quarry LP now owns 293 shares of the company's stock valued at $32,000 after purchasing an additional 209 shares during the last quarter. Chung Wu Investment Group LLC lifted its stake in shares of GeneDx by 8.2% in the 2nd quarter. Chung Wu Investment Group LLC now owns 3,300 shares of the company's stock worth $305,000 after purchasing an additional 250 shares during the period. Finally, Kovack Advisors Inc. boosted its holdings in shares of GeneDx by 14.3% in the third quarter. Kovack Advisors Inc. now owns 2,868 shares of the company's stock worth $309,000 after buying an additional 358 shares during the last quarter. 61.72% of the stock is owned by hedge funds and other institutional investors.
GeneDx Company Profile
(
Get Free Report)
GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
